Assetmark Inc. Raises Stock Position in Elevance Health, Inc. $ELV

Assetmark Inc. grew its stake in Elevance Health, Inc. (NYSE:ELV) by 28.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 86,775 shares of the company’s stock after buying an additional 19,078 shares during the quarter. Assetmark Inc.’s holdings in Elevance Health were worth $28,039,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ELV. Vanguard Group Inc. boosted its stake in shares of Elevance Health by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock worth $8,890,419,000 after acquiring an additional 704,790 shares in the last quarter. Sanders Capital LLC grew its holdings in Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after purchasing an additional 1,152,440 shares during the period. Artisan Partners Limited Partnership increased its position in shares of Elevance Health by 9.7% in the second quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock valued at $1,429,498,000 after buying an additional 324,399 shares in the last quarter. Norges Bank acquired a new position in shares of Elevance Health during the 2nd quarter worth approximately $1,148,379,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in Elevance Health by 4.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock worth $788,616,000 after acquiring an additional 112,020 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of ELV opened at $346.49 on Friday. The firm has a 50-day simple moving average of $352.22 and a two-hundred day simple moving average of $331.73. The stock has a market cap of $76.47 billion, a PE ratio of 13.79, a P/E/G ratio of 1.87 and a beta of 0.50. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is 27.23%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ELV shares. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Barclays lowered their price target on Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. UBS Group set a $400.00 price target on shares of Elevance Health in a research report on Thursday, January 29th. Finally, Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $390.55.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.